| Leslie R Horton, APRN | |
|
11109 S 84th St Ste 1820, Papillion, NE 68046-4133 | |
| (402) 827-1577 | |
| Not Available |
| Full Name | Leslie R Horton |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 3 Years |
| Location | 11109 S 84th St Ste 1820, Papillion, Nebraska |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457025223 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | 113663 (Nebraska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Chi Health Bergan Mercy | Omaha, NE | Hospital |
| Chi Health Midlands | Papillion, NE | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Alegent Creighton Clinic | 1951210418 | 827 |
News Archive
An experimental vaccine based on a virus that causes encephalitis in the wild appears to block tumor growth in some cases of advanced cancer, according to researchers at Duke University Medical Center. Scientists say the vaccine is able to stimulate an immune response, even in the face of profound immune system suppression, a condition most patients with advanced cancer experience.
The National Institutes of Health is expected to award up to $70 million over five years to three physician-scientists to launch the Alzheimer's Clinical Trials Consortium, which will create a network of 35 Alzheimer's disease trial sites across the country with the goal of finding new ways to treat or prevent Alzheimer's.
Merck, known as MSD outside the United States and Canada, today announced that company researchers will participate in two new collaborative efforts led by the prominent academic institutions of the University of North Carolina (UNC) Chapel Hill and the University of California San Francisco (UCSF) to develop new approaches towards eradicating HIV, the virus that causes AIDS.
"A pathological and very complex autoimmune reaction of the skin": This is the definition doctors and scientists use to describe psoriasis, a disease that affects one to three percent of the population.
Patients benefitted from an important design element in the pivotal phase III clinical trial that led to Food and Drug Administration and worldwide regulatory approval of sunitinib for the treatment of gastrointestinal stromal tumors resistant to the only other available therapy, according to a study in Clinical Cancer Research, a journal of the American Association for Cancer Research.
› Verified 8 days ago
| Entity Name | Alegent Creighton Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548287907 PECOS PAC ID: 1951210418 Enrollment ID: O20040407001314 |
News Archive
An experimental vaccine based on a virus that causes encephalitis in the wild appears to block tumor growth in some cases of advanced cancer, according to researchers at Duke University Medical Center. Scientists say the vaccine is able to stimulate an immune response, even in the face of profound immune system suppression, a condition most patients with advanced cancer experience.
The National Institutes of Health is expected to award up to $70 million over five years to three physician-scientists to launch the Alzheimer's Clinical Trials Consortium, which will create a network of 35 Alzheimer's disease trial sites across the country with the goal of finding new ways to treat or prevent Alzheimer's.
Merck, known as MSD outside the United States and Canada, today announced that company researchers will participate in two new collaborative efforts led by the prominent academic institutions of the University of North Carolina (UNC) Chapel Hill and the University of California San Francisco (UCSF) to develop new approaches towards eradicating HIV, the virus that causes AIDS.
"A pathological and very complex autoimmune reaction of the skin": This is the definition doctors and scientists use to describe psoriasis, a disease that affects one to three percent of the population.
Patients benefitted from an important design element in the pivotal phase III clinical trial that led to Food and Drug Administration and worldwide regulatory approval of sunitinib for the treatment of gastrointestinal stromal tumors resistant to the only other available therapy, according to a study in Clinical Cancer Research, a journal of the American Association for Cancer Research.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Leslie R Horton, APRN 7261 Mercy Rd, Omaha, NE 68124-2311 Ph: () - | Leslie R Horton, APRN 11109 S 84th St Ste 1820, Papillion, NE 68046-4133 Ph: (402) 827-1577 |
News Archive
An experimental vaccine based on a virus that causes encephalitis in the wild appears to block tumor growth in some cases of advanced cancer, according to researchers at Duke University Medical Center. Scientists say the vaccine is able to stimulate an immune response, even in the face of profound immune system suppression, a condition most patients with advanced cancer experience.
The National Institutes of Health is expected to award up to $70 million over five years to three physician-scientists to launch the Alzheimer's Clinical Trials Consortium, which will create a network of 35 Alzheimer's disease trial sites across the country with the goal of finding new ways to treat or prevent Alzheimer's.
Merck, known as MSD outside the United States and Canada, today announced that company researchers will participate in two new collaborative efforts led by the prominent academic institutions of the University of North Carolina (UNC) Chapel Hill and the University of California San Francisco (UCSF) to develop new approaches towards eradicating HIV, the virus that causes AIDS.
"A pathological and very complex autoimmune reaction of the skin": This is the definition doctors and scientists use to describe psoriasis, a disease that affects one to three percent of the population.
Patients benefitted from an important design element in the pivotal phase III clinical trial that led to Food and Drug Administration and worldwide regulatory approval of sunitinib for the treatment of gastrointestinal stromal tumors resistant to the only other available therapy, according to a study in Clinical Cancer Research, a journal of the American Association for Cancer Research.
› Verified 8 days ago
Elaine Preston, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 529 Pinnacle Dr, Papillion, NE 68046 Phone: 737-787-7809 | |
Caitlin M Carlson, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 701 Pinnacle Dr Ste 105, Papillion, NE 68046 Phone: 402-505-7989 | |
Jessica Gering, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 10701 S 72nd St, Ste 100, Papillion, NE 68046 Phone: 402-827-9400 Fax: 402-827-9405 | |
Mildred Pepple, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 11111 S 84th St, Papillion, NE 68046 Phone: 402-593-3131 Fax: 402-593-3117 | |
Nicole Schleisman, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 11650 S 73rd St, Papillion, NE 68046 Phone: 888-333-7520 | |
Ms. Michelle Maile Mccaslin, APRN, NP-C Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 10701 S 72nd St Ste 100, Suite 100, Papillion, NE 68046 Phone: 402-827-9421 Fax: 402-999-8029 | |
Mrs. Macy Ann Laux, APRN, FNP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 312 Olson Dr Ste 101, Papillion, NE 68046 Phone: 402-382-9117 |